257 related articles for article (PubMed ID: 16700847)
1. Low-molecular-weight heparin, bemiparin, in the outpatient treatment and secondary prophylaxis of venous thromboembolism in standard clinical practice: the ESFERA Study.
Santamaría A; Juárez S; Reche A; Gómez-Outes A; Martínez-González J; Fontcuberta J;
Int J Clin Pract; 2006 May; 60(5):518-25. PubMed ID: 16700847
[TBL] [Abstract][Full Text] [Related]
2. Optimal dosing of bemiparin as prophylaxis against venous thromboembolism in surgery for cancer: an audit of practice.
Balibrea JL; Altimiras J; Larruzea I; Gómez-Outes A; Martínez-González J; Rocha E;
Int J Surg; 2007 Apr; 5(2):114-9. PubMed ID: 17448976
[TBL] [Abstract][Full Text] [Related]
3. A comparative double-blind, randomised trial of a new second generation LMWH (bemiparin) and UFH in the prevention of post-operative venous thromboembolism. The Bemiparin Assessment group.
Kakkar VV; Howes J; Sharma V; Kadziola Z
Thromb Haemost; 2000 Apr; 83(4):523-9. PubMed ID: 10780310
[TBL] [Abstract][Full Text] [Related]
4. A prospective observational study on the effectiveness and safety of bemiparin, first dose administered 6 h after knee or hip replacement surgery.
Abad JI; Gómez-Outes A; Martínez-González J; Rocha E;
Arch Orthop Trauma Surg; 2007 Oct; 127(8):665-70. PubMed ID: 17089172
[TBL] [Abstract][Full Text] [Related]
5. Outpatient treatment of venous thromboembolism with low-molecular-weight heparin: an economic evaluation.
Huse DM; Cummins G; Taylor DC; Russell MW
Am J Manag Care; 2002 Jan; 8(1 Suppl):S10-6. PubMed ID: 11822346
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of the effectiveness and safety of bemiparin in a large population of orthopedic patients in a normal clinical practice.
Otero-Fernández R; Gómez-Outes A; Martínez-González J; Rocha E; Fontcuberta J;
Clin Appl Thromb Hemost; 2008 Jan; 14(1):75-83. PubMed ID: 17895506
[TBL] [Abstract][Full Text] [Related]
7. Economic and utilization outcomes associated with choice of treatment for venous thromboembolism in hospitalized patients.
Knight KK; Wong J; Hauch O; Wygant G; Aguilar D; Ofman JJ
Value Health; 2005; 8(3):191-200. PubMed ID: 15877591
[TBL] [Abstract][Full Text] [Related]
8. Treatment of pulmonary embolism: The use of low-molecular-weight heparin in the inpatient and outpatient settings.
Hull RD
Thromb Haemost; 2008 Mar; 99(3):502-10. PubMed ID: 18327398
[TBL] [Abstract][Full Text] [Related]
9. Extended thromboprophylaxis with low-molecular-weight heparins after hospital discharge in high-risk surgical and medical patients: a review.
Huo MH; Muntz J
Clin Ther; 2009 Jun; 31(6):1129-41. PubMed ID: 19695383
[TBL] [Abstract][Full Text] [Related]
10. Clinical experience with bemiparin.
Abad Rico JI; Lozano Sánchez FS; Rocha E
Drugs; 2010 Dec; 70 Suppl 2():25-33. PubMed ID: 21162607
[TBL] [Abstract][Full Text] [Related]
11. The outpatient treatment of deep vein thrombosis delivers cost savings to patients and their families, compared to inpatient therapy.
Rodger MA; Gagné-Rodger C; Howley HE; Carrier M; Coyle D; Wells PS
Thromb Res; 2003; 112(1-2):13-8. PubMed ID: 15013267
[TBL] [Abstract][Full Text] [Related]
12. Meta-analysis of venous thromboembolism prophylaxis in medically Ill patients.
Kanaan AO; Silva MA; Donovan JL; Roy T; Al-Homsi AS
Clin Ther; 2007 Nov; 29(11):2395-405. PubMed ID: 18158080
[TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness of bemiparin in the prevention and treatment of venous thromboembolism.
Gómez-Outes A; Berto P; Prandoni P
Expert Rev Pharmacoecon Outcomes Res; 2006 Jun; 6(3):249-59. PubMed ID: 20528519
[TBL] [Abstract][Full Text] [Related]
14. Outpatient treatment of pulmonary embolism with dalteparin.
Kovacs MJ; Anderson D; Morrow B; Gray L; Touchie D; Wells PS
Thromb Haemost; 2000 Feb; 83(2):209-11. PubMed ID: 10739374
[TBL] [Abstract][Full Text] [Related]
15. Subcutaneous adjusted-dose unfractionated heparin vs fixed-dose low-molecular-weight heparin in the initial treatment of venous thromboembolism.
Prandoni P; Carnovali M; Marchiori A;
Arch Intern Med; 2004 May; 164(10):1077-83. PubMed ID: 15159264
[TBL] [Abstract][Full Text] [Related]
16. Low molecular weight heparins: the optimal treatment for venous thromboembolism.
Daskalopoulos ME; Daskalopoulou SS; Liapis CD
Curr Med Res Opin; 2004 Jul; 20(7):1001-5. PubMed ID: 15265244
[TBL] [Abstract][Full Text] [Related]
17. Cost effectiveness of bemiparin sodium versus unfractionated heparin and oral anticoagulants in the acute and long-term treatment of deep vein thrombosis.
Gómez-Outes A; Rocha E; Martínez-González J; Kakkar VV
Pharmacoeconomics; 2006; 24(1):81-92. PubMed ID: 16445305
[TBL] [Abstract][Full Text] [Related]
18. Treatment of venous thromboembolism in patients with cancer: subgroup analysis of the Matisse clinical trials.
van Doormaal FF; Raskob GE; Davidson BL; Decousus H; Gallus A; Lensing AW; Piovella F; Prins MH; Büller HR
Thromb Haemost; 2009 Apr; 101(4):762-9. PubMed ID: 19350123
[TBL] [Abstract][Full Text] [Related]
19. Replacing inpatient care by outpatient care in the treatment of deep venous thrombosis--an economic evaluation. TASMAN Study Group.
van den Belt AG; Bossuyt PM; Prins MH; Gallus AS; Büller HR
Thromb Haemost; 1998 Feb; 79(2):259-63. PubMed ID: 9493572
[TBL] [Abstract][Full Text] [Related]
20. Pharmacoeconomic analysis of bemiparin and enoxaparin as prophylaxis for venous thromboembolism in total knee replacement surgery.
Honorato J; Gómez-Outes A; Navarro-Quilis A; Martínez-González J; Rocha E; Planès A
Pharmacoeconomics; 2004; 22(13):885-94. PubMed ID: 15329033
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
